Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)

Summary

A clinical study to determine the safety, efficacy and the way sitagliptin works in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control.

Timeline

Start

2007-02-14

Primary completion

2010-04-28

Completion

2010-04-28

Outcome

Met primary endpoint

registry Sitagliptin vs Placebo; p <0.001; Difference in Least-Squares Mean -111.0 (95% CI -158.0 to -63.9); ANCOVA NCT00704132 ↗

Publications

• Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, Astiarraga B, Chen Y, Alba M, Holst J, Ferrannini E. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab. 2012 Aug;97(8):2818-26. doi: 10.1210/jc.2012-1205. Epub 2012 Jun 8.

Drugs

Indications